Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUDSON GI: Benralizumab in Eosinophilic Gastritis/Gastroenteritis
NCT05251909Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of benralizumab in eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), sponsored by AstraZeneca. Started Jan 2022; status: terminated.
02
Drugs
benralizumab
03
Conditions
eosinophilic gastritis (EG)eosinophilic gastroenteritis (EGE)
Beyond the preview
Go deeper on NCT05251909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251909.